Pepgen Inc (PEPG)

$PEPG With its Enhanced Delivery Oligonucleotide platform, PepGen is tackling genetic diseases at their source. Learn more here! https://biotechhealthx.com/biotech-news/pepgen-pepg-s-poised-to-disrupt-rare-disease-therapy/

$PEPG Chart update: Stock continues to fail at the EMA 50 -- another rejection at overhead resistance keeps the downtrend intact. S-1 support at $1.18 is back in play, with S-2 at $0.88 marking the 52-week low. A sustained break of S-1 opens the door for a potential retest of that lower range. For those unfamiliar, the co announced it's discontinuing its DMD program after PGN-EDO51 failed to show meaningful dystrophin expression in the CONNECT1 trial. With DMD now off the table, all attention shifts to the DM1 program, but that still carries clinical risk heading into key data later this year and into 2026. BofA also lowered its PT to $1 on the back of the failed DMD results and ongoing uncertainty. Given both the technical and fundamental setup, a move toward that S-2 level remains very possible if support doesn't hold. Stay tuned. JMHO. GLTA

$PEPG 📉 PepGen price target lowered to $1 from $3 at BofA https://finance.yahoo.com/news/pepgen-price-target-lowered-1-130042923.html

$APVO $ATXG $CLGN $PEPG $PYPD will $CLGN go back up again should I hold

$PYPD $CLGN $ATXG $PEPG $APVO showed up today like they had 3 cups of espresso... up, down, all around

HC Wainwright & Co. has adjusted their stance on PepGen ( $PEPG ), setting the rating to Buy with a target price of 14 → 8.

$PEPG PepGen to discontinue DMD programs after PGN-EDO51 did not achieve target PepGen announced that based on the levels of dystrophin protein measured in the 10 mg/kg cohort of its CONNECT1-EDO51 study investigating PGN-EDO51 in Duchenne muscular dystrophy patients amenable to exon 51 skipping, the company will focus on advancing its "promising" myotonic dystrophy type 1 program currently in Phase 2 clinical development. The company is voluntarily discontinuing development of PGN-EDO51 and intends to wind down all DMD-related research and development activities. In the 10 mg/kg cohort of the CONNECT1 study, PGN-EDO51 increased exon 51 skipped transcripts to 4.26%; however, total dystrophin only increased to 0.59% of normal levels. The safety profile of PGN-EDO51 continued to be generally favorable and all treatment-related adverse events were mild in nature. No serious adverse events were reported in the study. "We are disappointed by the dystrophin results observed in the 10 mg/kg dose cohort in CONNECT1, as it was our hope that we could improve upon existing therapies for patients in a more profound way," said James McArthur, PhD, President and CEO of PepGen. "As we wind down our DMD program, we would like to thank the patients, families, caregivers, investigators and study staff for their support and participation in this research. I also want to acknowledge our team's hard work and commitment to advancing new potential treatments for DMD patients." PepGen continues to expect to report data from its FREEDOM-DM1 15 mg/kg cohort in patients with DM1 during the second half of 2025. FREEDOM is a Phase 1 single ascending dose, randomized, placebo-controlled clinical trial, with endpoints including safety, 28-day splicing correction and functional benefit measures. The company also continues to expect to report data from the 5 mg/kg cohort of its FREEDOM2-DM1 study in DM1 patients in the first quarter of 2026. FREEDOM2 is a Phase 2 multiple ascending dose, randomized, placebo-controlled clinical trial, with endpoints following four doses that include safety, splicing correction and functional benefit measures.

$PEPG PepGen just announced it's discontinuing its DMD program after the CONNECT1 trial failed to show meaningful dystrophin production at the 10 mg/kg dose. Exon skipping was confirmed (4.26% transcripts), but dystrophin only increased to 0.59% of normal -- a 0.36% mean increase, which isn’t enough to justify moving forward. The drug was generally well tolerated with only mild AEs, but the efficacy just didn’t meet the mark. As a result, they’re winding down all DMD-related R&D, including CONNECT2. Going forward, the focus shifts entirely to the DM1 program, where they've already reported 29% mean splicing correction at 10 mg/kg. That program still has two key data readouts: 15 mg/kg single-dose (FREEDOM-DM1) in 2H 2025 5 mg/kg multi-dose (FREEDOM2-DM1) in Q1 2026 Not great news, IMO. With DMD now off the table and DM1 the sole focus, the stock could remain under pressure in the near term as the market digests the update. Stay tuned. GLTA.

$PEPG multiple SEC Schedule 13G filings ahead of upcoming June 4th board meeting. https://archive.fast-edgar.com/20250515/AP2Z92228222A9Z2222A2ZOB3SVRZ222V272/ Could indicate voting new board members and or other business like raising capital or consolidation.

$PEPG rtw investment just sold all 3m shares.